2-[(S)-1-Phenylethylamino]-4-[5-N-(N-methylcarbamoyl)aminobenzimidazol-1-yl]pyrimidine | 317826-17-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 2-[(S)-1-Phenylethylamino]-4-[5-N-(N-methylcarbamoyl)aminobenzimidazol-1-yl]pyrimidine
• 英文别名: 1-methyl-3-[1-[2-[[(1S)-1-phenylethyl]amino]pyrimidin-4-yl]benzimidazol-5-yl]urea
• CAS: 317826-17-8
• 化学式: C₂₁H₂₁N₇O
• 分子量: 387.444
• InChiKey: CUBPDLILMLMOOO-AWEZNQCLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  96.8
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-[(S)-1-phenylethylamino]-4-[5-aminobenzimidazol-1-yl]pyrimidine 、 异氰酸甲酯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 2-[(S)-1-Phenylethylamino]-4-[5-N-(N-methylcarbamoyl)aminobenzimidazol-1-yl]pyrimidine
  参考文献：
  名称：

  Disubstituted pyrimidines as Lck inhibitors

  摘要：

  We have developed a family of 4-benzimidazolyl-N-piperazinethyl-pyrimidin-2-amines that are subnanomolar inhibitors of Lck. A subset of these Lck inhibitors, with heterocyclic substituents at the benzimidazole C5, are also low-nanomolar inhibitors of cellular IL2 release. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.07.102

文献信息

• Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)one derivatives
  申请人：SANOFI-SYNTHELABO

  公开号：EP1340760A1

  公开（公告）日：2003-09-03

  The invention relates to a pyrimidone derivative represented by formula (I) or a salt thereof: wherein: X represents two hydrogen atoms, a sulphur atom, an oxygen atom or a C1-2 alkyl group and a hydrogen atom; Y represents a bond, a ethenylene group, a ethynylene group, an oxygen atom, a sulphur atom, a sulfonyl group, a sulfoxide group, a carbonyl group, a nitrogen atom being optionally; or a methylene group optionally substituted; R1 represents a pyrimidine group optionally substituted; R2 may represent a C1-6 alkyl group optionally substituted by a C6,10 aryloxy or a C6,10 arylamino group ; a C3-6 cycloalkyl group, a C1-4alkylthio group, a C1-4alkoxy group, a C1-2 perhalogenated alkyl group, a C1-3 halogenated alkyl group, a phenylthio group, a benzyl group, a phenyl ring, an indanyl ring, a 5,6,7,8-tetrahydronaphthyl ring, a naphthyl ring, a pyridine ring, a pyrrole ring, a thiophene ring, a furan ring or an imidazole ring ; R3 and R4 represents each independently a hydrogen atom, C1-6 alkyl group, a hydroxy group, a C1-4alkoxy group or a halogen atom; R5 represents a hydrogen atom, a C1-6 alkyl group or a halogen atom; The invention relates also to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β or GSK3β and cdk5/p25, such as Alzheimer disease.

  本发明涉及式 (I) 所代表的嘧啶酮衍生物或其盐： 其中 X 代表两个氢原子、一个硫原子、一个氧原子或一个 C1-2 烷基和一个氢原子； Y 代表一个键、一个乙烯基、一个乙炔基、一个氧原子、一个硫原子、一个磺酰基、一个亚砜基、一个羰基、一个任选被取代的氮原子或一个任选被取代的亚甲基； R1 代表任选被取代的嘧啶基团； R2 可代表被 C6,10 芳氧基或 C6,10 芳酰胺基任选取代的 C1-6 烷基；C3-6环烷基、C1-4烷硫基、C1-4烷氧基、C1-2过卤代烷基、C1-3卤代烷基、苯硫基、苄基、苯基环、茚基环、5,6,7,8-四氢萘环、萘基环、吡啶环、吡咯环、噻吩环、呋喃环或咪唑环； R3 和 R4 各自独立地代表氢原子、C1-6 烷基、羟基、C1-4 烷氧基或卤素原子； R5 代表氢原子、C1-6 烷基或卤原子； 本发明还涉及一种包含上述衍生物或其盐作为活性成分的药物，该药物用于预防和/或治疗由 GSK3β 或 GSK3β 和 cdk5/p25 活性异常引起的神经退行性疾病，如阿尔茨海默病。
• SRC KINASE INHIBITOR COMPOUNDS
  申请人：Merck & Co., Inc.

  公开号：EP1206265A1

  公开（公告）日：2002-05-22
• EP1206265A4
  申请人：——

  公开号：EP1206265A4

  公开（公告）日：2002-08-07
• US6498165B1
  申请人：——

  公开号：US6498165B1

  公开（公告）日：2002-12-24
• [EN] SRC KINASE INHIBITOR COMPOUNDS<br/>[FR] COMPOSES INHIBITEURS DE LA SRC KINASE
  申请人：MERCK & CO INC

  公开号：WO2001000213A1

  公开（公告）日：2001-01-04

  Pyrimidine compounds (Formula I), or their pharmaceutically acceptable salts, hydrates, solvates, crystal forms and individual diastereomers, and pharmaceutical compositions including the same, which are inhibitors of tyrosine kinase enzymes, and as such are useful in the prophylaxis and treatment of protein tyrosine kinase-associated disorders, such as immune diseases, hyperproliferative disorders and other diseases in which inappropriate protein kinase action is believed to play a role, such as cancer, angiogensis, atherosclerosis, graft rejection, rheumatoid arthritis and psoriasis.